NCT02885870

Brief Summary

The spinal cord is a common site for the development of several neurodegenerative neurological disorders (spinal muscular atrophy or SMA, amyotrophic lateral sclerosis or ALS, X-linked spinal bulbar muscular atrophy or SBMA). In different proportions, these diseases involve axonal loss in large funiculi of the spinal white matter, their demyelination, and loss of ventral horn motor neurons or motoneurones of the spinal gray matter. The lack of specific biomarkers of these macro and microscopic spinal damages, makes it difficult the differential diagnosis and monitoring of these diseases. Techniques to explore non-invasively the human central nervous system, such as magnetic resonance imaging (MRI) and electrophysiology, are potential tools to extract specific biomarkers of spinal damages. However, imaging techniques are still poorly developed at spinal level for technical (specific antennas), anatomical (size of the spinal cord, vertebrae) and physiological reasons (cardio-respiratory movements). However, recent advances in the field of spinal cord imaging allowed to extract quantitative data on neuron loss, axonal degeneration and demyelination in different spinal pathologies whether degenerative (ALS or SMA) or traumatic (SCI). Correlations were found with clinical data, and in ALS patients, the changes in MRI metrics over time paralleled the functional deterioration. The electrophysiological techniques are used since a long time, leading to a good knowledge of the neurophysiology of human spinal cord. In addition, electrophysiology indirectly provides data at a microscopic scale, providing information on the excitability of spinal neural networks and giving an estimate of the amount of functional neurons. By combining these techniques for the investigation of human spinal cord in vivo, the goal is to extract new biomarkers using as study models, diseases of the spinal cord affecting differentially the white and the gray matter (SMA, SBMA and ALS). At first, new methods of diffusion MRI and modelling will be performed in healthy subjects to assess the axonal density and diameter of the fibers in the white matter. The anatomical imaging T2 will measure the geometrical parameters of the spinal cord such as its surface and/or volume at a given vertebral level. Thanks to imaging, we will construct via methods of segmentation and image processing, an atlas of the spinal cord that will allow to locate spatially spinal atrophy in patients. After this phase of validation, A study of patients will be conducted using these new MRI techniques, in addition to those already developed in the laboratory. The contribution of electrophysiology will be to assess more accurately the microscopic damage. Quantitative data from imaging and electrophysiology will be correlated with clinical data in order to extract the most relevant biomarkers. This project has thus a methodological interest by proposing the development of new methods to assess the human spinal cord, at both macro and microscopic levels. These methods are based on the development of the techniques developed at spinal level and which are already applicable to human pathologies. The original combination of imaging and electrophysiology will also enable us to further analyze the human spinal cord, both anatomically and functionally. This project has an important clinical value for the extraction of biomarkers in diseases where there is an unmet need for diagnosis, monitoring, prognosis and evaluation of new therapies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 18, 2016

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 22, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 1, 2016

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 27, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 27, 2019

Completed
Last Updated

January 12, 2021

Status Verified

January 1, 2021

Enrollment Period

2.9 years

First QC Date

August 22, 2016

Last Update Submit

January 10, 2021

Conditions

Keywords

biomarkerspinal cord diseaseresonance imagingelectrophysiology

Outcome Measures

Primary Outcomes (1)

  • Change in MRI from baseline to follow-up visit

    Assessment of the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration.

    Baseline, 6 months (amyotrophic lateral sclerosis patients) or 18 months (Spinal muscular atrophy and X-linked spinobulbar muscular atrophy patients)

Study Arms (2)

Patient

EXPERIMENTAL

Patient with : * Spinal muscular atrophy (n=25) * X-linked spinobulbar muscular atrophy (n=25) * Amyotrophic lateral sclerosis (n=25)

Procedure: Combination of multiparametric MRI and electrophysiology

Healthy subject

EXPERIMENTAL

Subject without any neurologic or spine affection Subject matched for sex and age with patient arm

Procedure: Combination of multiparametric MRI and electrophysiology

Interventions

MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis

Healthy subjectPatient

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Spinal muscular atrophy patients :
  • Slowly progressive weakness related to pure lower motor neuron involvement X-linked spinobulbar muscular atrophy patients
  • Diagnosis confirmed by genetic testing (expansion of CAG trinucleotide repeats in the androgen receptor gene) Amyotrophic lateral sclerosis patients
  • ALS definite or probable according to El Escorial criteria - No bulbar or breathing impairment preventing decubitus
  • Healthy volunteers
  • \- Subjects without any neurologic or spine affection - Subjects matched for sex and age

You may not qualify if:

  • Subjects not able to understand the investigator
  • Subjects who are not affiliated to the national health insurance fund
  • Contraindications to resonance imaging
  • Contraindication to transcranial magnetic stimulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

La Pitie Salpetrieres

Paris, 75013, France

Location

MeSH Terms

Conditions

Spinal Cord Diseases

Condition Hierarchy (Ancestors)

Central Nervous System DiseasesNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2016

First Posted

September 1, 2016

Study Start

April 18, 2016

Primary Completion

February 27, 2019

Study Completion

February 27, 2019

Last Updated

January 12, 2021

Record last verified: 2021-01

Locations